Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

ANCA Associated Vasculitis Clinical Trials

10 recruiting trials for ANCA Associated Vasculitis. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
10
Total Trials
10
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06462768

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage...

Sponsor: CHU de ReimsEnrolling: 2601 location
RECRUITINGPhase 1 / Phase 2NCT06685042

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

The CATARSIS study explores the use of anti-CD19 CAR T-cell therapy as a novel approach for treating refractory systemic autoimmune diseases, specifically SLE, SSc, DM/PM, and...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 81 location
RECRUITINGEarly Phase 1NCT06548607

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD19 or...

Sponsor: Nanjing Bioheng Biotech Co., Ltd.Enrolling: 201 location
RECRUITINGNCT06373081

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.

Sponsor: Shanghai Changzheng HospitalEnrolling: 61 location
RECRUITINGNCT06508346

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-CD19 CAR-T cells in the treatment of childhood-onset refractory ANCA-Associated...

Sponsor: The Children's Hospital of Zhejiang University School of MedicineEnrolling: 121 location
RECRUITINGNCT06794827

Early-access Avacopan in Real-world ANCA-associated Vasculitis

The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient...

Sponsor: Leiden University Medical CenterEnrolling: 1001 location
RECRUITINGPhase 1NCT06285279

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

This study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval)...

Sponsor: Nanjing University School of MedicineEnrolling: 241 location
RECRUITINGPhase 4NCT05965284

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

This study is a prospective, open-labelled, randomized, controlled, single-center clinical trial. The aim of this study is to compare the remission rate of patients treated with...

Sponsor: Chinese SLE Treatment And Research GroupEnrolling: 401 location
RECRUITINGNCT04664465

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid...

Sponsor: University Hospital, BrestEnrolling: 30011 locations
RECRUITINGPhase 2NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Sponsor: Peking University People's HospitalEnrolling: 501 location

Frequently Asked Questions

There are currently 10 clinical trials for ANCA Associated Vasculitis, with 10 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for ANCA Associated Vasculitis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for ANCA Associated Vasculitis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.